Gastroenterology Flashcards

1
Q

Definition of cholelithiasis

A

Presence of solid concretions in the gallbladder

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Definition of choledocholithiasis

A

Gallstones form in the gallbladder but may exit into bile ducts

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Epidemiology of Cholelithiasis / Choleidocholethiasis and Biliary colic

A

10-15% of all adults in europe.
Asymptomatic in >80% of people. Once developed, 50% will go on to have recurrent pain while 3% develop complications. Asymptomatic 0.1-2% will experience a major complication each year.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Aetiology: Cholelithiasis / Choleidocholethiasis and Biliary colic

A

90% gallstones composed of cholesterol and form in the gallbladder

15% gallstones are black pigment stones consisting of polymerised calcium bilirubinate.

Brown pigment stones form in bile ducts as a result of stasis and infection. Consist of calcium bilirubinate (unconjugated bilirubin), calcium salts of long chain fatty acids and cholesterol. Usually develop from bacterial infection or partial biliary obstruction.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Risk Factors : Cholelithiasis / Choleidocholethiasis and Biliary colic

A

5F’s
Female
Fertile - pregnancy
Forty - Age
Family history
Fat - Obesity / Diabetes / Metabolic syndrome

Others:
Gene mutations
NAFLD
Rapid weight loss
Medications
Hispanic and Native-american ethnicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Pathophysiology: Cholelithiasis / Choleidocholethiasis and Biliary colic

A

Occurs as a result of 3 defects: Bile supersaturated with cholesterol, Accelerated nucleation and gallbladder hypermobility.

Cholesterol supersaturation occurs when the liver excretes excessive amounts of cholesterol compared with its solubilising agents e.g. bile salts and lecithin.
Precipitation of cholesterol microcrystals then follows initiated by presence of nucleating agents (mucin). Impaired gallbladder contractility causes stagnation and retention in gallbladder, and microcrystals collect and grow into gallstones.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Key presentations: Cholelithiasis / Choleidocholethiasis and Biliary colic

A

RUQ or epigastric pain that typically increases in intensity and may last several hours. Can radiate to the upper back or right shoulder.
Postprandial pain - Onset of pain approx 1 hour after eating.
Pain also in sleep when lying down.

Signs - Response to analgesia and >15-20 mins but <8 hour increments.

Symptoms - Dyspepsia, heartburn, flatulence, bloating,

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Investigations: Cholelithiasis / Choleidocholethiasis and Biliary colic

A

1st line
LFT’s
Choleliathiasis - Normal
Choledocholeliathiasis - elevated alkaline phosphatase and bilirubin, ALP
Brief biliary obstruction with stone passage = early transient elevation in Alanine aminotransferase ALT before alkaline phosphatase ALP rises.
FBC - Normal
Serum Lipase and Amylase - Normal

GOLD STANDARD: Abdominal Ultrasound - Stones in the gallbladder or bile duct with or without bile duct dilation.

Others:
MRCP - bile duct dilated in choledocholiathiasis
EUS - Stones present
Abdo CT - Stones. Refer if USS normal but having biliary pain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Management of Cholelithiasis / Choleidocholethiasis and Biliary colic

A

Biliary colic - NSAIDS - diclofenac or indomethacin. Paracetamol may be sufficient. With anti-spasmodic if needed (hyoscine).
Patients with symptomatic gallstones but no signs of cholecystitis then offer laparoscopic cholecystectomy.
Offer bile duct clearance of laparoscopic cholecystectomy to patients with bile duct stones. Clear bile duct either ERCP or surgically.
Advise patients to avoid triggering foods and symptoms to watch out for.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Complications of Cholelithiasis / Choleidocholethiasis and Biliary colic

A

Acute cholecystitis
ERCP associated pancreatitis
Acute cholangitis
Acute biliary pancreatitis
Mirizzi syndrome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Prognosis: Cholelithiasis / Choleidocholethiasis and Biliary colic

A

Recurrent bile duct stones occur in 5-20% people after endoscopic sphincterotomy.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

DDx: Cholelithiasis / Choleidocholethiasis and Biliary colic

A

Acute Cholecystitis / Pancreatitis - Elevated WBC count, serum lipase and or amylase elevated >3 times.

Peptic ulcer disease - H pylori breath / stool antigen test positive. EGD - peptic ulcer

Gallbladder cancer - CT abdo shows intrahepatic mass lesion

Acalculous cholecystitis - No gallstones but murphy’s sign

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Definition of acute cholangitis

A

Biliary obstruction with inflammation and bacterial seeding and growth in biliary tree.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Epidemiology acute cholangitis

A

1% of patients with cholelithiasis. Male to female ratio is equal.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Aetiology: acute cholangitis

A

Cholelithiasis
Choledocholelithiasis and biliary obstruction
Iatrogenic biliary duct injury
Sclerosing cholangitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Risk Factors: acute cholangitis

A

Cholelithiasis
Choledocholelithiasis and biliary obstruction
Iatrogenic biliary duct injury
Sclerosing cholangitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Pathophysiology acute cholangitis

A

Obstruction of the common bile duct results in bacterial seeding of biliary tree. Sludge forms, providing a growth medium for bacteria and as obstruction progresses, bile duct pressure increases.
This forms a pressure gradient causing extravasation of bacteria into the bloodstream and if not treated can lead to sepsis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Clinical manifestations: acute cholangitis

A

Key Presentations
Presence of risk factors
RUQ pain or epigastric pain with abdominal tenderness
Jaundice
Pyrexia

Signs
Pale stools
Pruritus
Hypotension
Mental changes

Symptoms
Malaise, Fatigue, Nausea, Vomiting,

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Investigations: acute cholangitis

A

1st Line
FBC - WCC >10x109 with low platelets
Raised serum urea and creatinine
ABG - raised lactate and low bicarbonate
LFTs - hyperbilirubinemia and raised serum transaminases and alkaline phosphatase.
CRP - raised
Serum potassium and magnesium - decreased
Transabdominal USS - dilated bile duct or common bile duct stones.

Gold Standard
ERCP - direct observation of obstruction and adequate clearance with therapy.

Others
MRCP - mass impinging on biliary tree, stricture
PTC - bile duct stone or other obstruction
EUS - Common Bile Duct stones, ampullary, pancreatic and or biliary masses.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Criteria: acute cholangitis

A

A Either fever or lab data of inc WCC
B Jaundice, Lab data of abnormal LFT (ALP, AST, ALT)
C Biliary dilation or evidence of aetiology on imaging

Diagnosis suspected : One in A and one in B or C
Definitive diagnosis : One in A, plus one in B, plus one in C

Grade III - Acute cholangitis with onset of dysfunctions from another organ / system e.g. Neurological or cardiovascular dysfunction.
Grade II - Any two of abnormal WCC, Fever, >75 years and hyperbilirubinemia or hypoalbuminemia.
Grade I - no criteria of grade II or III.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Management - acute cholangitis

A

TREAT SUSPECTED SEPSIS FIRST
Give broad spectrum IV antibiotics and IV hydration - Piperacillin or tazobactam. (Metronidazole in combination with gentamicin is an alternative to penicillin allergy.)
Correct electrolyte imbalances
Analgesia
ERCP or (PTC if contraindications)
Switch to specific antibiotic regimen once results back
Consider cholecystectomy and continue to monitor bloods.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Complications - acute cholangitis

A

Acute pancreatitis
Inadequate biliary drainage after procedure
Hepatic abscess

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Prognosis of Acute cholangitis

A

Rapid clinical improvement once biliary drainage has occurred. Those who have severe underlying medical conditions and those whose decompression is delayed prognosis is poorer.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

DDX of acute cholangitis

A

Acute cholecystitis - Positive murphy’s sign
Peptic ulcer disease - LFTs typically normal
Acute pancreatitis - Amylase and lipase greater elevation and CT shows stranding
Hepatic abscess - USS, CT or MRI
Acute Appendicitis - CT of abdo shows fat stranding around appendix.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Definition of Primary Biliary Cholangitis
Chronic disease of the small intrahepatic bile ducts that is characterised by excessive bile duct damage. Fibrosis develops as a consequence and toxic bile acids eventually lead to cirrhosis.
26
Epidemiology Primary Biliary Cholangitis
35/100,000 with peak age 55-65 years. Patients in their 20s can also present more aggressive forms, less likely to respond to treatment. More prevalent in European and western countries
27
Aetiology Primary Biliary Cholangitis
Coeliac Disease Scleroderma Other autoimmune diseases
28
Risk factors Primary Biliary Cholangitis
Main: Female sex Age between 45-65 Others: Family history Smoking UTI
29
Pathophysiology Primary Biliary Cholangitis
Damage to and progressive destruction of biliary epithelial cells lining small intrahepatic ducts. This can lead to bile duct loss causing cholestasis and bile acid retention, which can lead to fibrosis or eventually cirrhosis.
30
Clinical manifestations Primary Biliary Cholangitis
Key Presentations Personal history of autoimmune disease or history of hypercholesterolaemia Signs Hepatomegaly Symptoms Dry eyes and mouth fatigue itch sleep disturbance Postural dizziness Possible jaundice and ascites Finger clubbing / cholesterol deposits Xanthelasma
31
Investigations Primary Biliary Cholangitis
1st Line LFT - ALT, AST, ALP and Gamma-GT all elevated Serum Albumin - decreased AMA and ANA - present Abdominal ultrasound scan and magnetic resonance cholangiopancreatography - excludes obstructive lesion with visible bile ducts. Gold Standard Blood test AMA positive Others Liver biopsy - bile duct lesions Prothrombin time - prolonged Serum immunoglobulin - elevated IgM and IgG Transient elastography - decreased liver elasticity.
32
Criteria Primary Biliary Cholangitis
Cholestatic liver biochemistry (elevated LFT) Compatible serological tests (AMA and or PBC specific ANA) Compatible liver histology
33
Management Primary Biliary Cholangitis
Early stage: Bile acid analogue - ursodeoxycholic acid If have significant inflammatory component then immunomodulatory therapy With cholestatic pruritus - antipruritic therapy With fatigue - lifestyle modification For end stage liver disease - Liver transplantation.
34
Complications Primary Biliary Cholangitis
Hypercholesterolaemia Osteoporosis Portal hypertension secondary to cirrhosis Hepatoma
35
Prognosis Primary Biliary Cholangitis
Slow progression X2 risk of mortality with or without a liver disease Impaired quality of life with side effects.
36
DDx Primary Biliary Cholangitis
Obstructive bile duct lesion - much more prominent pain and bacterial cholangitis much more likely Small-duct primary sclerosing cholangitis - Associated with IBD and more common in younger males. PSC marker present. Drug induced cholestasis - Antibody not associated and history of relevant drug exposure Cholestasis of pregnancy Infiltrative malignancy within the liver - liver biopsy.
37
Definition cholecystitis
Acute gallbladder inflammation. Complete cystic duct obstruction which leads to inflammation of the gallbladder wall. In 5% cases, bile stasis can block the cystic duct, causing acalculous cholecystitis.
38
Epidemiology cholecystitis
Occurs in 10% of symptomatic patients. 3x more common in women than men up to the age of 50 years.
39
Aetiology cholecystitis
Gallstones Starvation, TPN, narcotic analgesics immobility EBV
40
Risk factors cholecystitis
Main: Cholelithiasis Total parenteral nutrition (TPN) Diabetes Medications Others: Physical inactivity, Low fibre, Trauma, Infections
41
Pathophysiology cholecystitis
Fixed obstruction or passage of gallstones into the gallbladder neck or cystic duct can cause acute inflammation of the gallbladder wall. The impacted gallstone causes bile to be trapped in the gallbladder, which causes irritation and increases pressure. This stimulates prostaglandin synthesis which mediates an inflammatory response and can result in secondary bacterial infection if untreated. It may resolve spontaneously 5-7 days after onset.
42
Clinical manifestations Cholecystitis
Key Presentations Pain and tenderness in RUQ or epigastric area which can radiate to back Fever Palpable mass Signs Murphy's sign, Pyrexia Symptoms Nausea, Malaise, Anorexia, vomiting
43
Investigations cholecystitis
1st Line FBC - elevated WCC CRP, Bilirubin, AST, ALT and Gamma-GT elevated Serum lipase / amylase elevated Abdo USS - distended and thickened gallbladder >3mm. With pericholecystic fluid CT or MRI - irregular thickening of gallbladder wall, increased density of fatty tissue and gas in gallbladder wall or lumen. Gold Standard Ultrasonography - Ultrasound - murphy's sign. Others MRCP EUS
44
Management cholecystitis
Analgesia, fluid resuscitation and antibiotics Laparoscopic cholecystectomy
45
Complications cholecystitis
Suppurative cholecystitis Bile duct injury due to surgery Gallstone ileus Cholecystoenteric fistulas
46
Prognosis cholecystitis
If gallbladder perforates, mortality is 30%. Untreated acute acalculous cholecystitis is associated with up to 50% mortality.
47
DDx cholecystitis
Cholangitis - Has jaundice whereas cholecystitis doesn't Chronic cholecystitis - persistent Peptic ulcer disease - normal LFT GORD - more heartburn and acid reflux than right pain. Pancreatitis - amylase and lipase elevated more.
48
Definition Acute Pancreatitis
Disorder of the exocrine pancreas and is associated with acinar cell injury with local and systemic inflammatory responses.
49
Epidemiology Acute Pancreatitis
56/100,000 a year and is one of the most common GI diseases leading to hospital admission. Approx 50% caused by gallstones and 25% by alcohol. More common in women >60 yo and more common in with patients with microlithiasis.
50
Aetiology Acute Pancreatitis
Gallstones Ethanol Trauma Steroids Mumps Autoimmune diseases Scorpion Hypercalcaemia ERCP Drugs GET SMASHED
51
Risk factors Acute Pancreatitis
Main: Middle aged women and young-middle aged men Hypertriglyceridemia Causative drugs Trauma ERCP Others: Hypercalcaemia Coxsackievirus Pancreatic cancer
52
Pathophysiology Acute Pancreatitis
Abnormal intracellular calcium accumulation causes an increase in calcium transients. This causes premature activation of zymogens leading to enzyme activation which destruct acinar cells, leading to an inflammatory response. Ethanol-induced pancreatitis as ethanol has direct toxic result on acinar cell, causing inflammation and enzyme destruction.
53
Clinical manifestations Acute Pancreatitis
Key Presentations Mid-epigastric or LUQ pain that radiates to the back. Sudden onset and constant and severe and is worse with movement. Tripoding relieves pain Signs Diminished bowel sounds if ileus has developed. Hypotension, oliguria, hyperhidrosis, Past medical history / risk factors. Grey turner / cullens sign Symptoms Nausea, Vomiting, Anorexia,
54
Investigations Acute Pancreatitis
1st Line Serum Lipase and Amylase - >3 times normal (3-5 upper limit in diabetes) FBC - WBC count >12x10 9 or <4 x 10 9. Elevated haematocrit >44% (pancreatic necrosis) CRP >200mg/L = Pancreatic necrosis Elevated urea and creatinine LFT - high ALT >3 times limit signals gallstones as cause. Gold Standard Blood serum lipase and amylase Others Abdo ultrasound - confirms presence of gallstones
55
Classifications Acute Pancreatitis
Mild acute - no organ failure or local or systemic complications Moderate acute - presence of transient organ failure (resolves in 48 hours) and or local complications or exacerbation of comorbidity Severe - persistent organ failure >48 hours and local complications common. Peripancreatic fluid collections, pancreatic and peripancreatic necrosis, pseudocysts and walled off necrosis. Radiological classification: Balthazar A Normal B Focal or diffuse gland enlargement with small intra-pancreatic fluid collection C Peripancreatic inflammatory changes and <30% gland necrosis D Any of above plus single extra-pancreatic fluid and 30-50% necrosis E Extensive extra-pancreatic fluid, pancreatic abscess and >50% gland necrosis.
56
Management Acute Pancreatitis
Early-goal fluid resuscitation with crystalloid fluid plus analgesia Establish oral feeding as soon as patient can tolerate it. Gallstone - arrange emergency endoscopic retrograde cholangiopancreatography ERCP within 24 hours Alcohol related - alcohol abstinence programme Do not request CECT in first 3-4 days as it cannot detect necrosis that early Consider supplemental oxygen, antiemetic, IV antibiotics (if infection is confirmed) and nutritional support with severity assessment
57
Complications Acute Pancreatitis
Acute renal failure Pancreatic abscess Chronic pancreatitis Sepsis ARDS Pancreatic effusion
58
Prognosis Acute Pancreatitis
80% recovery in 3-5 days. 25-30% in severe pancreatitis mortality.
59
DDx Acute Pancreatitis
Peptic ulcer disease - Normal or low lipase / amylase. Intestinal obstruction - normal lipase and amylase Cholangitis - normal lipase and amylase Cholecystitis - normal or slightly elevated lipase and amylase with RUQ pain and thickened gallbladder wall on USS.
60
Definition Chronic Pancreatitis
Recurrent or persistent abdominal pain and progressive injury to the pancreas and surrounding structures - resulting in scarring and loss of function.
61
Epidemiology Chronic Pancreatitis
Hereditary - age 10-14 years Juvenile idiopathic chronic pancreatitis - 19-23 years Alcoholic acute pancreatitis - 36-44 years and senile at 56-62 years. More prevalent in men over the age of 45 years.
62
Aetiology Chronic Pancreatitis
TIGAR-O Toxins - alcohol, smoking, CKD, Hypercalcaemia/lipidaemia Idiopathic Genetic Autoimmune Recurrent and severe acute pancreatitis Obstruction
63
Risk Factors Chronic Pancreatitis
Main: Smoking High fat / protein diet Genetic predisposition Coeliac Others: Psoriasis Tropical geography Coxsackievirus.
64
Pathophysiology Chronic Pancreatitis
Persistent cytokine secretion, pancreatic stellate cells secrete collagen stimulating fibrosis and chronic pancreatitis.
65
Clinical Manifestations Chronic Pancreatitis
Key Presentations Presence of risk factors, Abdominal pain in LUQ and epigastric region and Steatorrhoea Signs Weight loss and malnutrition Symptoms Nausea, vomiting, Dyspnoea
66
Investigations Chronic Pancreatitis
1st Line CT / MRI - pancreatic calcifications, focal or diffuse enlargement of pancreas and or vascular complications Gold Standard CT/MRI Others EUS - only used if diagnosis is still in question which will show ductal and parenchymal abnormalities s-MRCP - abnormal exocrine function
67
Management Chronic Pancreatitis
Acute pain - smoking and alcohol cessation Persistent pain - Alcohol and smoking cessation, analgesia, PPI and pancreatic enzymes. Dietary modifications
68
Complications Chronic Pancreatitis
Pancreatic exocrine insufficiency Diabetes mellitus Pancreatic calcifications Opioid addiction Pancreatic duct obstruction
69
Prognosis Chronic Pancreatitis
Generally pain decreases or disappears overtime. 10 year survival is 20-30% lower than general population Most common cause of death is pancreatic carcinoma.
70
DDx Chronic Pancreatitis
Pancreatic cancer - CT/MRI may show mass or lesion Mesenteric ischaemia Biliary colic Peptic ulcer disease Acute pancreatitis Intestinal obstruction
71
Definition: Alcoholic Liver disease
Alcoholic liver disease has 3 stages of liver damage: Steatosis, Alcoholic hepatitis and alcoholic liver cirrhosis.
72
Epidemiology: Alcoholic Liver disease
3 millions deaths annually worldwide. Approx 40-80g/day in men and 20-40g/day in women for 10-12 years. There is approximately 14g in one shot of alcohol. 14.2 million people >18 years have alcohol use disorder and of these 9 million were men.
73
Aetiology: Alcoholic Liver disease
Chronic alcohol use and alcoholism.
74
Risk Factors: Alcoholic Liver disease
Main: Obesity Smoking - hepatocellular carcinoma Others: HCV Female
75
Pathophysiology: Alcoholic Liver disease
Alcohol is metabolised by alcohol dehydrogenase and cytochrome P450 2E1. Alcohol dehydrogenase converts alcohol to acetaldehyde which is then converted to acetate by acetaldehyde dehydrogenase. This process converts NAD to NADH, which in excess inhibits gluconeogenesis and increases fatty acid oxidation. When there is not enough acetaldehyde dehydrogenase, it binds to cellular proteins and produces acetaldehyde adducts which stimulate an immune response, causing inflammation and necrosis by neutrophils. Cytochrome P450 2E1, increases production of free radicals through oxidation of NADPH to NADP. This creates more ROS. Improper metabolism of these ROS can stimulate hypoxia inducible factor 1 alpha - which increases TNF, and further intensifies immune response that leads to tissue injury. Alcohol also damages intestinal mucosa, leading to endotoxemia, ending in hepatic inflammation.
76
Clinical manifestations: Alcoholic Liver disease
Key Presentations Asymptomatic RU abdominal discomfort with acute alcoholic hepatitis Signs Hepatomegaly, Ascites, malnutrition, (Splenomegaly, jaundice, palmar erythema, asterixis) Symptoms Weight changes, anorexia, fatigue
77
Investigations: Alcoholic Liver disease
1st Line Serum AST and ALT - men >30 units/l women >19 and ratio of AST/ALT >2. Can be decreased with excessive necrosis Serum ALP and gamma GT - normal or elevated Serum bilirubin - elevated Serum albumin - low FBC - anaemia, leukocytosis, thrombocytopenia, high MCV U+E - high urea, low electrolytes. Hepatic ultrasound Gold Standard LFT’s Others Viral hepatitis serology which will indicate absence of antigens. CT abdo Liver biopsy
78
Management: Alcoholic Liver disease
Alcohol abstinence and alcohol withdrawal management Consider: Weight reduction and smoking cessation Nutritional supplementation Immunisation - HAV and HBV Liver Transplant - only if alcohol abstinent for >3 months Corticosteroids - hepatic encephalopathy
79
Complications: Alcoholic Liver disease
Hepatic encephalopathy - buildup of harmful toxins - ammonia. Portal hypertension - slowing of intrahepatic blood flow causing a backup of blood in portal vein GI bleeding Renal failure / hepatorenal syndrome - altered renal blood flow in response to altered blood flow in liver Sepsis - bacterial infections high with cirrhosis
80
Prognosis: Alcoholic Liver disease
Alcoholic fatty liver returns to normal with alcohol abstinence. 5 year survival of those with cirrhosis if they stop drinking is 90% compared with 70% if they continue. Glasgow alcoholic hepatitis score with a higher score indicating a worse prognosis.
81
DDx: Alcoholic Liver disease
Viral hepatitis - presence of antibodies Cholecystitis - presence of gallstones and positive murphy's sign. Acute liver failure Wilson’s disease - increased urinary copper
82
Definition NAFLD
NAFLD is the presence of hepatic steatosis without secondary causes of hepatic fat e.g. alcohol. Occurs when intrahepatic fat is >= 5% of liver weight. NAFLD - presence of hepatic steatosis without evidence of hepatocellular injury in the form of hepatocyte ballooning NASH - Non-alcoholic steatohepatitis - hepatic steatosis and ballooning, with or without fibrosis. This can lead to liver failure.
83
Epidemiology NAFLD
>25% worldwide. Median age is 53 years but can occur at any age.
84
Aetiology NAFLD
HCV Wilson's disease Starvation Parenteral nutrition Medications Acute fatty liver of pregnancy Metabolic disorders
85
Risk Factors NAFLD
Main: Obesity - truncal / central Insulin resistance or diabetes Dyslipidaemia Metabolic syndrome Rapid weight loss Medications Total parenteral nutrition Others: HCV Wilsons Lipodystrophy
86
Pathophysiology NAFLD
Insulin resistance leading to accumulation of excessive triglyceride axxumulation in the liver and development of steatosis. Once developed, additional injury or oxidative injury can cause the necro-inflammatory component seen in steatohepatitis. Antioxidant deficiency, hepatic iron, fat derived hormones (leptin and resistin) and intestinal bacteria have been linked to NASH development from NAFLD.
87
Clinical manifestations NAFLD
Key Presentations Presence of risk factors, absence of significant alcohol abuse, mild abnormality in LFT and truncal obesity Signs Hepatosplenomegaly Symptoms Fatigue, Malaise, RUQ abdominal discomfort
88
Investigations NAFLD
1st Line LFT - AST, ALT, ALP, GGT, Bilirubin normal or slightly elevated FBC - Anaemia and thrombocytopenia in cirrhosis and PHTN Metabolic panel - abnormal and hyponatremia Lipid panel - elevated total cholesterol, LDL, TGLY and low HDL. Gold Standard Liver Biopsy Others INR prothrombin - normal or elevated. Serum albumin - normal or decreased. Viral hepatitis - antibody negative Liver ultrasound - abnormal echotexture. Elastography - liver stiffness Abdo MRI - increased liver fat content Fasting insulin - elevated.
89
Management NAFLD
Weight loss with healthy diet and exercise Pioglitazone - improves liver histological scores but be aware of side effects of potential weight gain Vitamin E Weight loss pharmacotherapy - Orlistat prevents absorption of fats Gastric bypass - BMI >40 or >35 with at least one other obesity related comorbidity considered for bariatric surgery.
90
Complications NAFLD
Ascites Variceal Haemorrhage Hepatocellular carcinoma Cirrhosis → liver failure Death - advanced stage 3 or 4 fibrosis
91
Prognosis NAFLD
NASH associated with increased mortality over 14 years, usually as a result of CVD or other comorbidity rather than liver causes. Recurrent NAFLD is 20-100% after liver transplantation. Mortality increases as the fibrosis stage increases.
92
DDx NAFLD
ALD - AST/ALT ratio >2 Cryptogenic cirrhosis Autoimmune hepatitis - antibody tests and hyperglobulinemia Viral hepatitis - presence of antibodies Haemochromatosis - elevated ferritin and iron saturation Primary biliary cholangitis - significant elevation in ALP, GGT and IgM Wilsons - elevated urinary copper and elevated hepatic copper.
93
Definition: chronic liver disease
Pathological end stage of any chronic liver disease, characterised by fibrosis and conversion of normal liver architecture to structurally abnormal nodules
94
Epidemiology: chronic liver disease
In Europe, cirrhosis related to either Viral infection or alcohol abuse were the main indications of a liver transplant. 1.5 billion people worldwide have chronic liver disease.
95
Aetiology: chronic liver disease
NAFLD ALD Viral hepatitis Any chronic liver disease Cryptogenic - idiopathic
96
Risk Factors: chronic liver disease
Main: Alcohol misuse IV drug misuse Unprotected intercourse Obesity Country of birth - HBV and HCV. Others: Blood transfusions Tattoos
97
Pathophysiology: chronic liver disease
Hepatic fibrosis occurs from hepatic stellate cells and leads to an accumulation of collagen I and III in hepatic parenchyma. With activation, stellate cells become contractile leading to increased portal resistance during liver fibrosis and cirrhosis. This leads to portal hypertension, development of ascites and gastro-oesophageal varices. Compensated cirrhosis - Cirrhosis investigations present but liver synthetic function is preserved and generally no complications Decompensated cirrhosis - Cirrhosis investigations present and liver synthetic function is decreased and development of complications such as PHTN, Variceal bleeding, hepatic encephalopathy and jaundice.
98
Clinical manifestations: chronic liver disease
Key Presentations Ascites and abdominal distension Jaundice and pruritus Haematemesis (blood in vomit) and Melaena (black stool) Signs Palmar erythema, Spider naevi, leukonychia, hepatosplenomegaly, distension and collateral circulation, hepatic fetor, Peripheral oedema - salt retention. Symptoms Fatigue, weakness, weight loss,
99
Investigations: chronic liver disease
1st Line LFTs - AST/ALT >=1 - cirrhosis. GGT elevated Serum albumin and sodium - reduced Serum potassium and prothrombin time - elevated Platelet count - reduced Depending upon aetiology - viral hepatitis antibodies may be positive. Gold Standard Liver Biopsy Others Abdo CT/MRI - liver surface nodularity with reduced liver size. USS or EUS /\ Liver elastography
100
Management: chronic liver disease
Treatment of underlying chronic liver disease Monitoring - USS, CT, EUS, MRI Supportive and palliative care Sodium restriction and diuretic therapy for ascites / oedema Liver transplantation
101
Complications: chronic liver disease
Ascites Gastro-oesophageal varices Malnutrition and Sarcopenia Hepatocellular carcinoma Bleeding and thrombosis Hepatorenal syndrome.
102
Prognosis: chronic liver disease
10 year survival with compensated cirrhosis is 90% with decompensated 50% Mean survival time for decomp is 2 years 4 stages of cirrhosis: No varices or ascites - 1% mortality per year Varices with no bleeding, no ascites - 4% With ascites with or without varices and no bleeding - 20% GI bleeding due to PHTN with or without ascites - 57%
103
DDx: chronic liver disease
Budd-Chiari syndrome - Doppler ultrasound and CT - absence of hepatic vein filling Portal vein thrombosis - MRI normal hepatic venous pressure but doppler and abdo CT show portal vein filling defect Constrictive pericarditis Idiopathic portal hypertension - Liver biopsy shows no evidence of cirrhosis
104
What is Portal Hypertension
PHTN - Portal hypertension is characterised by a pathologic increase in portal venous pressure that leads to the formation of an extensive network of portosystemic collaterals that divert a large fraction of portal blood to the systemic circulation, bypassing the liver. Blood backs up in nearby veins in the oesophagus and stomach, causing varices.
105
When do varices occur during liver disease
Esophageal varices develop when normal blood flow to the liver is blocked by a clot or scar tissue in the liver. To go around the blockages, blood flows into smaller blood vessels that aren't designed to carry large volumes of blood.
106
What is haematemesis
Vomiting fresh blood. This occurs as a result of bleeding occurring in any part of the upper gastrointestinal tract.
107
Definition Hepatic Encephalopathy
Brain dysfunction caused by advanced liver insufficiency and or portosystemic shunt.
108
Epidemiology Hepatic Encephalopathy
30-40% of patients with cirrhosis develop HE within their illness. HE occurs in 55% of patients with a TIPS procedure within 2 years.
109
Aetiology: Hepatic Encephalopathy
High ammonia levels GI bleeding Hypokalaemia Metabolic encephalopathy Brain atrophy Brain oedema
110
Risk Factors: Hepatic Encephalopathy
Cirrhosis Acute hepatic failure Portacaval shunt Hypovolaemia, GI bleeding Excessive protein intake Hypokalemia or hyponatremia Hypoxia and metabolic alkalosis.
111
Pathophysiology: Hepatic Encephalopathy
Impaired LFT leads to impaired ammonia clearance, which can alter cerebral concentration of amino acids and affect neurotransmitter synthesis and electrical activity. It can also lead to increased intracellular astrocyte osmolarity, inducing astrocyte swelling and can lead to raised ICP. Patients with decompensated cirrhosis have altered intestinal microbiome and can lead to an overgrowth in potentially pathogenic bacteria, leading to pro-inflammatory cytokines such as IL1 and TNF. Systemic inflammation activates microglia in the brain producing neuroinflammation.
112
Clinical Manifestations: Hepatic Encephalopathy
Key Presentations Altered mental status, confusion, mood and motor disturbances Signs Ataxia, bradykinesia, hypokinesia, slow monotonous speech, coma, hyper-reflexia and nystagmus. Palmar erythema, jaundice, hepatomegaly, ascites Symptoms Euphoria, depression, insomnia or hypersomnia,
113
Investigations Hepatic Encephalopathy
1st Line LFT - abnormal Serum electrolytes - normal or hyponatremia / kalcemia FBC - normal or leukocytosis or thrombocytosis Blood ammonia - Raised CT scan - absence of other causes and presence of oedema Gold Standard Psychometric Hepatic Encephalopathy Score PHES. Others EEG - decrease in brain wave frequency and amplitude.
114
Management: Hepatic Encephalopathy
Supportive care, reversal of precipitating factors and investigation of alternative causes Lactulose - helps draw water from body into colon and soften stool. It also decreases intestinal production and absorption of ammonia. Rifaximin - all those with symptoms persisting after lactulose or those contraindicated to lactulose. Branches chain amino acids Consider transplant or shunt.
115
Complications: Hepatic Encephalopathy
Death Falls Neurological deficits Re-admission
116
Prognosis: Hepatic Encephalopathy
42% 1 year survival and 23% 3 year survival. When patient is at grade 4 (coma), mortality is at 80%.
117
DDx: Hepatic Encephalopathy
Brain tumours - MRI Subdural haematoma - CT shows haemorrhage Acute stroke - CT shows haemorrhage or infarct Meningitis - Lumbar puncture shows cloudy CSF.
118
Definition HAV
RNA virus with a faecal oral route of transmission. Most infections in adults and older children are symptomatic. Average incubation is 28 days. Not associated with chronic liver disease. 70% develop jaundice.
119
Epidemiology HAV
In developed countries, outbreaks are associated with contaminated food and water. High prevalence in Africa, Asia and Latin america. Mainly occur in early childhood. Vaccination to prevent this.
120
Aetiology HAV
Close contact with an infected person Contaminated food and or water
121
Risk Factors: HAV
Main: Living in or travelling to endemic region Close personal contact with infected person Homosexual men Homelessness and illegal drug use. Known foodborne outbreak Others: Occupational exposure - healthcare
122
Pathophysiology: HAV
Virus transported to intestinal epithelium then through mesenteric veins to liver. Virus enters hepatocytes and replicates, is then excreted in bile and blood from infected hepatocytes. Liver injury is when cytotoxic T cells lyse the infected hepatocytes. Viral particles are then excreted in stools.
123
Clinical Manifestations: HAV
Key Presentations Travel Fever Malaise Nausea and vomiting Jaundice RUQ pain Signs Hepatomegaly, clay coloured stools, Dark urine Symptoms Fatigue, Headache and pruritus
124
Investigations: HAV
1st Line LFT - ALT and AST, bilirubin elevated U+E - elevated blood urea and serum creatinine Prothrombin - slightly prolonged of 11-26 seconds Gold Standard IgM anti-hepatitis A test - positive - active infection IgG anti-hepatitis A test - may be positive - will show recovery or recent infection Others Hepatitis A RNA detection - used if others inconclusive.
125
Management: HAV
If known exposure <2weeks then immunisation if not already. If confirmed Hep A - rest and recovery with supportive care. If acute liver failure - liver transplant VERY RARE
126
Complications: HAV
Acalculous cholecystitis Pancreatitis
127
Prognosis: HAV
85% full recovery within 3 months. <1% patients have a fulminant course of illness and refer to liver transplant. 1 year expectancy with liver transplant for acute HAV is 69%.
128
DDx: HAV
Other viral hepatitis - detected through serology of viral antibodies. EBV - negative serology for all types of hepatitis and EBV IgG and IgM positive Coxsackievirus - atypical lymphocytes but no viral hep serology Autoimmune hepatitis - serum gamma-globulin more than 2x normal and sometimes have ANA antibodies. Alcohol hepatitis - AST/ALT ratio of at least 2. FBC show anaemia, leukocytosis and or thrombocytopenia.
129
Defintion HBV
DNA virus transmitted by percutaneous and permucosal routes. Can be prevented with immunisation
130
Epidemiology HBV
Most common liver infection globally. People from endemic areas (africa and asia) at increased risk. 350-400 million of the world population has chronic hepatitis B
131
Aetiology HBV
Infected needles Unprotected sex Unsanitary conditions Childbirth
132
Risk factors HBV
Main: Perinatal exposure to infant born with HBV positive mother High risk sexual behaviours IV drug use Born in highly endemic region Family history Others: Occupational workers Infected with HIV Possible haemodialysis
133
Pathophysiology HBV
HBsAg - outer surface of virus (surface antigen) HBcAg - Core of the virus (core antigen) Viral DNA + E antigen (HBeAg) shows active replication and infection. Causes an immune response and removal of HBV infected cells via CD8+ T lymphocytes. At onset of virus, HBsAg and Viral DNA with HBeAg will be present. HBsAg for >6months indicates chronic infection
134
Clinical manifestations of HBV
Key Presentations Presence of risk factors and asymptomatic. Signs VERY RARE - Liver common symptoms and signs
135
Investigations for HBV
1st Line LFT - elevated AST, ALT and ALP with bilirubin. Decreased albumin FBC - microcytic anaemia and or thrombocytopenia U+E - hyponatremia and high urea Gold Standard Serum hepatitis B surface antigen or e antigen - Positive (in active onset or chronic) Serum hepatitis B antibody to both surface and core antigen - positive in IgG and IgM Others Test for coinfections
136
Management of HBV
Supportive care - 95% of immunocompetent will achieve antibodies Antiviral therapy (entecavir) or liver transplant in those with acute liver failure In pregnant women give tenofovir disoproxil
137
Complications of HBV
Fulminant hepatic failure Cirrhosis Hepatocellular carcinoma Hep B associated glomerulonephritis.
138
Prognosis HBV
20% will develop chronic HBV. Children under 6 at increased risk as 50% to chronic HBV and % increases with decreasing age.
139
DDX HBV
Other viral hepatitis EBV - no viral antibodies HSV - HSV IgM and HSV PCR positive Acute alcoholic hepatitis - Negative for viral hepatitis Autoimmune hepatitis - serum gamma-globulin more than 2x normal and sometimes have ANA antibodies.
140
Definition HVC
Percutaneous exposure to infected blood. Inflammation of the liver caused by hepatitis C virus. Chronic infection causes liver inflammation and fibrosis - leading to development of cirrhosis, liver failure or liver cancer over 20-50 years.
141
Epidemiology HVC
58 million people have hep C. European and eastern mediterranean regions have the highest prevalence rate. Genotype 1 is most prevalent worldwide.
142
Aetiology HCV
Blood transmission Injections Sexual activity - homogenous Haemodialysis and Perinatally
143
Risk factors HCV
Main: Unsafe medical practices IV or intranasal drug use Blood transfusions Heavy alcohol use HIV Others: Haemodialysis Healthcare workers Multiple sex partners Tattoos or body piercings.
144
Pathophysiology of HCV
Persistent infection appears due to weak CD4+ and CD8+ T cell responses during acute infection which fail to control viral replication. Liver damage is driven from local immune responses which triggers fibrogenesis.
145
Clinical manifestations HCV
Key Presentations Presence of risk factors Asymptomatic Signs RARELY - Liver condition symptoms.
146
Investigations HCV
1st Line Hep C antibody-enzyme immunoassay - Positive indicates current or past infection Serum aminotransferases - elevated. Gold Standard Hepatitis C RNA polymerase chain reaction - Indicates presence of active infection Others Liver biopsy - inflammation or fibrosis Test for co-infection - Hep B
147
Management HCV
Antiviral therapy e.g. glecaprevir Treatment of cirrhosis or acute liver failure accordingly.
148
Complications HCV
Cirrhosis Hepatocellular carcinoma Rheumatological conditions Treatment related HBV reactivation
149
Prognosis HCV
Europe - 5 year 91% survival and 10 year 79% with compensated cirrhosis 5 years 50% with decompensated survival .
150
Ddx HCV
Chronic hep B Alcoholic liver disease Steatohepatitis - USS shows fatty liver and Hep C antibody test negative Haemochromatosis - iron is abnormal
151
Definition Autoimmune hepatitis
Chronic inflammatory disease of the liver of unknown aetiology.
152
Epidemiology Autoimmune hepatitis
Female adults and children more commonly affected than males AIH type 1 more common in women affecting age 10-60 Type 2 affects children.
153
Aetiology Autoimmune hepatitis
Unknown
154
Risk factors Autoimmune hepatitis
Main: Genetic predisposition Female Others: Other viral hepatitis EBV Drugs or herbal agents
155
Pathophysiology Autoimmune hepatitis
Alteration in T-cell function and or B cell function. Type 1 - ANA and smooth muscle antibody (SMA) positive Type 2 - Anti-liver kidney microsomal-1 or anti liver cytosol specific positive.
156
Clinical manifestations Autoimmune hepatitis
Key Presentations Fatigue / Malaise/ anorexia and abdominal discomfort. Signs Hepatomegaly / Jaundice Symptoms Pruritus, nausea, fever, spider angioma, arthralgia.
157
Investigations Autoimmune hepatitis
1st Line LFT - raised AST, ALP, Gamma GT and ALT and bilirubin Serum globulin - increased Serum albumin - decreased Prothrombin time - Increased Gold Standard Liver biopsy - periportal lesion or interface hepatitis. Others ANA and SMA test - elevated in type 1 Anti LC1 - positive in type 2
158
Management Autoimmune hepatitis
Acute severe - High dose corticosteroids - methylprednisolone sodium succinate or prednisolone. AIH and primary biliary cirrhosis - Corticosteroid plus immunosuppressant and ursodeoxycholic acid.
159
Complications Autoimmune hepatitis
Osteoporosis, Truncal obesity, DM or hypertension - due to corticosteroid therapy Hepatocellular carcinoma Infections - due to immunosuppressant Liver failure.
160
Prognosis Autoimmune hepatitis
Untreated 5 year survival 50% and 10 year 10%. 10 year survival with treated 90% 20 year with cirrhosis is 40% or 80% without.
161
DDx Autoimmune Hepatitis
Primary biliary cirrhosis - ALP and Gamma glutamyl transferase raised more. AMA and ANA present. Liver biopsy shows bile duct lesion or periductal fibrosis. Chronic Hepatitis - Presence of other viral hepatitis antibodies Alpha 1 antitrypsin deficiency - low serum level Wilsons - Serum copper decreased with excessive urinary copper excretion.
162
Definition Infective Diarrhoea
Escherichia coli gram negative rod shaped bacterium that colonises the gastrointestinal tract. Ecoli becomes pathogenic by acquiring virulence factors or genetic mutations. Infection of pathogenic strains through ingestion of contaminated food or water.
163
Epidemiology Infective Diarrhoea
Older people, infants and people who are immunocompromised are more susceptible to infection and secondary complications. Can also be associated with UTI and pneumonia.
164
Aetiology Infective Diarrhoea
80% from enterohemorrhagic Ecoli (EHEC) infection 70% from enterotoxigenic E coli (ETEC) infection 30% from other types. Norovirus Rotovirus - most common cause
165
Risk Factors Infective Diarrhoea
Main: Ingestion of contaminated food Travel Poor hygiene Infantile or advanced age Others: Immunocompromised state Contact with infected animals
166
Pathophysiology Infective Diarrhoea
Escherichia coli is a gram negative rod shaped bacteria that propels itself via flagella. Diarrhoea is caused by a combination of intestinal inflammation, loss of absorptive surface and increased mucosal permeability and ion secretion.
167
Clinical manifestations Infective Diarrhoea
Key Presentations History of travel, contact with contaminated food or contact with infected people. Diarrhoea - bloody or watery. Signs Volume depletion - dry mucous, reduced skin turgor and tachycardia or hypotension Symptoms Abdominal pain, fever, nausea, anorexia and lethargy.
168
Investigations Infective Diarrhoea
1st Line Stool cultures - positive for pathogenic E coli FBC - elevated leukocyte count, low haemoglobin and or platelets Renal function and electrolytes - raised urea and creatinine, Hypokalaemia Gold Standard / Others Blood cultures - positive for e coli Abdominal x ray - bowel wall thickening Abdo CT - mural thickening of colon.
169
Complications Infective Diarrhoea
Haemolytic uraemic syndrome Bacteraemia IBS
170
Prognosis Infective Diarrhoea
Most are asymptomatic and self limiting with average recovery 2-5 days. Foodborne enterohemorrhagic E Coli - Fatality of up to 2% in industrialised countries with higher rates of older people and children. Enterotoxigenic E coli - fatality of 0.1% in industrialised countries.
171
Ddx Infective Diarrhoea
Viral gastroenteritis - shorter duration of 24-48 hours and no stool bacteria. Alternative gastroenteritis / travellers diarrhoea - stool cultures will identify alternative pathogen e.g. salmonella, shigella Amoebiasis - stool sample will show entamoeba Crohns - more chronic history, slower onset and prolonged diarrhoea and weight loss.
172
Management Infective Diarrhoea
Rehydration and supportive therapy - preferably glucose containing as glucose promotes absorption of sodium and water in intestinal lumen Bismuth subsalicylate - reduce diarrhoea. Antibiotic for moderate to severe cases - ciprofloxacin or rifamycin
173
Definition Haemochromatosis
A group of autosomal recessive disorders of iron metabolism.
174
Epidemiology Haemochromatosis
HFE related occurs primarily in norther european descent. 1 in 10 white people heterozygous for C282Y. Clinical disease more common in men. Typically age 30-50
175
Aetiology Haemochromatosis
Mutations in the HFE gene - C282Y and H63D Alcoholism Dysmetabolic syndrome
176
Risk factors Haemochromatosis
Middle age Male sex White ancestry Family history Supplemental iron
177
Pathophysiology Haemochromatosis
C282Y - hepatic hepcidin gene expression is low and macrophages continually release iron from erythrophagocytosis. Leads to an elevation in serum iron and transferrin saturation. Clinical manifestations are said to be caused by direct result of pro-oxidant effects iron has on organs - e.g. the liver where excess iron causes fibrosis.
178
Classifications Haemochromatosis
Type 1: Hereditary HFE Autosomal recessive mutation of HFE gene on chromosome 6 1A = mutation in C282Y. 1B = C282Y and H63D. 1C = HFE S65C Type 2: Juvenile A = mutation of the hemojuvelin gene 1p21 B = Hepcidin gene 19q13 Type 3: Transferrin receptor 2 Mutation in 7q22. Type 4: Ferroportin SLC40A1 gene 2q32.
179
Clinical manifestations Haemochromatosis
Key Presentations Mainly asymptomatic Calcium pyrophosphate crystal deposition, with pseudogout and chronic arthropathy - 2nd and 3rd metacarpophalangeal joints and proximal interphalangeal joints. Signs Hepatomegaly, Hypogonadism, Diabetes Symptoms Fatigue, weakness, lethargy.
180
Investigations Haemochromatosis
1st Line Serum transferrin saturation >45% Serum ferritin >674 picomoles in men and >449 in women Gold Standard HFE mutation analysis. Others HFE mutation analysis - C282Y homozygosity or C282Y/H63D heterozygosity etc. Liver biopsy - raised iron content LFT - aminotransferases above normal Fasting blood sugar - raised ECG and Echo - Dilated Cardiomyopathy and T wave flattening Hormones - lowered
181
Criteria Haemochromatosis
Stage 0 = C282Y homo with normal transferrin and ferritin with no clinical symptoms. Stage 1 = C282Y homo and increased transferrin and normal ferritin with no symptoms. Stage 2 = C282Y homo with both increased transferrin and serum ferritin but no symptoms Stage 3 = C282Y homo both increased transferrin and ferritin with mild clinical symptoms affect life Stage 4 = Same as stage 3 but with clinical symptoms manifesting organ damage.
182
Management Haemochromatosis
Stage 0 = Patients monitored every 3 years with history, examination and BT Stage 1 = Patients monitored once yearly. Stage 2/3/4 = Phlebotomy every 1-4 weeks or 2-3 times yearly depending on stage by removing 7mL/kg blood per session to get levels in check. Avoid Alcohol, Vit C and iron supplements.
183
Complications Haemochromatosis
Cirrhosis Diabetes Mellitus Chronic congestive heart failure - fluid overload and arrhythmias. HCC - hepatocellular carcinoma. Hypogonadism Bone loss
184
Prognosis Haemochromatosis
Mean survival was 21 years and most will establish iron-overload related disease. 11% increase risk of dying from cancer.
185
Ddx Haemochromatosis
Iron overload from chronic transfusion or anaemias - no HFE mutations Hep B and Hep C - Positive hep serology without homozygous HFE mutations Excessive iron supplementation - absence of homozygosity for HFE mutations.
186
Definition Wilsons Disease
Autosomal recessive disease of copper accumulation and toxicity caused by a defect in the ATP7B causing a defect in the enzyme metal P type ATPase involved in the excretion of copper within hepatocytes.
187
Epidemiology Wilsons Disease
Between 1 in every 30,000-50,000 people. All sexes and ethnic groups were affected equally. Appears around age 10-40.
188
Aetiology Wilsons Disease
Genetic mutation in ATP7B gene
189
Risk factors Wilsons Disease
History of hepatitis Family history ATP7B gene mutation
190
Pathophysiology Wilsons Disease
ATP7B loads copper onto apoceruloplasmin to make ceruloplasmin and transports excess copper into bile. Loss of ATP7B function leads to lack of copper incorporation and it cannot be transported into bile and excreted into faeces. Copper accumulation exceeds liver capacity and is excreted into blood and accumulates in the tissues. High levels of copper cause toxicity by oxidant damage which results in cell injury, inflammation and death.
191
Classifications Wilsons Disease
H1 = Acute hepatic - acutely occurring jaundice, either due to hepatitis like illness or coombs negative haemolytic disease. May progress to liver failure H2 = Chronic hepatic - any type of chronic liver disease with or without symptoms and may lead to or present as decompensated cirrhosis. N1 = associated with symptomatic liver disease N2 = not associated with Nx = presence or absence of liver disease not investigated.
192
Clinical manifestations Wilsons Disease
Key Presentations Presence of kayser-fleischer rings Signs Acute liver failure, Tremor, Dysarthia, Dystonia, incoordination, poor handwriting Symptoms Behavioural abnormalities, depression, personality change
193
Investigations Wilsons Disease
1st Line LFT - elevated AST and ALT and bilirubin with low albumin. INR - prolonged 24 hour urinary copper - >100mg Slit-lamp exam - KF rings of gold-brown pigment representing copper deposition in the membrane of descemet of the cornea. Serum ceruloplasmin - <200mg/L Gold Standard 24 hour urinary copper - >100mg (>40 is suggestive) Others FBC - anaemia or low WBC/platelet count Liver biopsy - liver copper >250mg/g Non-ceruloplasmin bound copper concentrations (NCC) - elevated DNA testing for ATP7B mutations
194
Management Wilsons Disease
Liver transplantation in hepatic failure In mild hepatic failure - Oral chelation therapy plus zinc and dietary restriction of copper. Zinc inhibits intestinal absorption of copper. Penicillamine - oral chelator that promotes renal excretion of copper.
195
Complications Wilsons Disease
Liver failure
196
Prognosis Wilsons Disease
Normally if treatment started early, patients have a normal quality of life or in mild cases liver damage can recover.
197
DDx Wilsons Disease
Hepatitis - hep antibody positive Alpha 1 antitrypsin deficiency - Enzyme is deficient Autoimmune hepatitis - positive AMA and ANA antibody Steatohepatitis - fatty liver and inflammation on biopsy
198
Defintion Alpha 1 Antitrypsin Deficiency
Autosomal codominant genetic disorder from allele mutations in the SERPINA1 gene at the protease inhibitor (PI) locus.
199
Epidemiology Alpha 1 Antitrypsin Deficiency
Mean age that smokers with AAT deficiency present is 32-41 years. Liver involvement present in neonates and is the second most common cause of liver transplantation in children.
200
Aetiology Alpha 1 Antitrypsin Deficiency
PI allele
201
Risk factors Alpha 1 Antitrypsin Deficiency
Family history of AAT deficiency Male Smoker aged 32-41
202
Pathophysiology Alpha 1 Antitrypsin Deficiency
PI allele mutations in the rSERPINA1 gene that cause ineffective activity of specific protease inhibitor AAT, which is responsible for neutralising neutrophil elastase and preventing inflammatory tissue damage in the lungs. Variants of the enzyme may also polymerise and accumulate in the liver, causing hepatic failure.
203
Clinical manifestations Alpha 1 Antitrypsin Deficiency
Key Presentations Productive cough Dyspnoea on exertion Current cigarette smoker Signs Hepatomegaly, Ascites, Chest hyperinflation Symptoms Wheezing
204
Investigations Alpha 1 Antitrypsin Deficiency
1st Line Plasma AAT level <20 micromol/L Pulmonary function testing - signif reduce in FEV1, FVC, FEV1/FVC, increased TLC Cxr - large lung volume and basilar predominant emphysema Chest CT - panacinar emphysema and or bronchiectasis LFT - elevated AST, ALT, ALP and bilirubin Gold Standard Plasma AAT level <20 micromol/L Isoelectric focusing - AAT varients Others Genotyping - AAT alleles Gene sequencing - SERPINA1 mutation Exercise testing with ABG - reduced PaO2 and elevated A-a gradient
205
Management Alpha 1 Antitrypsin Deficiency
Smoking cessation, Pollution avoidance, Hepatitis vaccination With pulmonary manifestations - Standard COPD treatment and AAT augmentation therapy Hepatic - Standard liver disease treatment and alcohol avoidance
206
Complications Alpha 1 Antitrypsin Deficiency
HCC Necrotising panniculitis
207
Prognosis Alpha 1 Antitrypsin Deficiency
No cure but many have normal lifespans. Between 50-72% deaths are caused by respiratory failure Liver fibrosis occurs in 20-36% of asymptomatic adults with PI*ZZ AAT deficiency. ⅓ patients with advanced age and a homozygous phenotype will due to complications with PHTN and primary liver cancer.
208
DDx Alpha 1 Antitrypsin Deficiency
COPD - long period of smoking and advanced age Asthma - clinically indistinguishable, reversibility of obstruction is partial in AAT deficient emphysema but fully in asthma Bronchiectasis - marked dilation of airways on CT Viral hepatitis - viral serology markers ALD - Altered Gamma GT, AST and ALT
209
Definition Hepatic Cancer
Hepatocellular carcinoma (hepatoma) is a primary cancer arising from hepatocytes in a predominantly cirrhotic liver.
210
Epidemiology Hepatic Cancer
6th most common cause of cancer worldwide and 2nd leading cause of cancer related death. 44% cases of HCC worldwide are from chronic HBV. Mean age of diagnosis - 46 in africa, up to 60 in US and Europe.
211
Aetiology Hepatic Cancer
Cirrhosis HBV HCV Diabetes Mellitus
212
Risk factors Hepatic Cancer
Cirrhosis Heavy alcohol consumption Viral hepatitis Diabetes Family history Obesity Cigarette smoking AAT deficiency Oral contraceptives Haemochromatosis
213
Pathophysiology Hepatic Cancer
Chronic HBV and HCV with metabolic conditions may lead to ROS from oxidative stress, that cause damage to DNA resulting in mutation of P53 gene. HBV is a direct carcinogen and may cause methylation of the p16 gene which is known to cause hepatocellular carcinogenesis causing HCC.
214
Clinical manifestations Hepatic Cancer
Key Presentations All key symptoms of liver damage e.g. Ascites, Jaundice, RUQ pain, Hepatic encephalopathy Signs Weight loss, Splenomegaly, Palmar erythema, spider naevi, Oedema Symptoms Early satiety, Fatigue, Diarrhoea
215
Investigations Hepatic Cancer
1st Line FBC - anaemia and or thrombocytopenia U+E - high urea and hyponatremia LFT - Elevated ALT, AST, ALP, bilirubin and low albumin INR - prolonged AFP - elevated USS - poorly defined margins and coarse, irregular internal echos Gold Standard Liver biopsy - poorly differentiated hepatocytes with large multinucleated giant cells having central necrosis
216
Management Hepatic Cancer
Stage 0 / A or very early - consider resection, thermal ablation or transplant Stage B - TACE or TARE or percutaneous ablation Stage C - atezolizumab and bevacizumab Stage D - Hospice care
217
Complications Hepatic Cancer
Biliary obstruction Cachexia Hypoglycaemia Hepatic failure
218
Prognosis Hepatic Cancer
5 year survival is 20% in general or 0-10% if symptomatic Non cirrhotic patients treated with surgical resection is 42% at 5 years Those with a transplant - 75% 4 year survival rate Stage D - 50% survival at <3 months
219
DDx Hepatic Cancer
Cholangiocarcinoma - INR and transaminases mildly elevated or normal. Hepatic adenoma - Doppler shows venous pattern instead of arterial hypervascularization of HCC Haemangioma of liver - normal LFT and alpha fetoprotein
220
Definition Ascites
Pathological collection of fluid in the peritoneal cavity.
221
Aetiology Ascites
Portal hypertension Cirrhosis Chronic liver disease Congestive heart failure Hypoalbuminemia Fulminant hepatitis
222
Clinical manifestations Ascites
Key Presentations Abdominal distension and tenderness. Signs Fluid on physical exam with shifting dullness Symptoms Early satiety, SOB,
223
Investigations Ascites
1st Line USS, CT or MRI
224
Management Ascites
Abdominal paracentesis
225
Complications Ascites
Spontaneous bacterial peritonitis
226
Prognosis Ascites
If SBP 10-28% mortality rate.
227
Ddx Ascites
HCV ALD Congestive heart failure
227
Definition Pancreatic Cancer
Primary pancreatic ductal adenocarcinoma. Goes from pre-invasive pancreatic intraepithelial neoplastic lesions to invasive ductal adenocarcinoma.
228
Aetiology Pancreatic Cancer
Cigarette smoking Hereditary pancreatitis Family history
229
Risk Factors Pancreatic Cancer
Smoking Family history pancreatic cancer Family history of other hereditary cancers
230
Epidemiology Pancreatic Cancer
Most common at age 65-75 years and generally presents late. Median age was 70 and median age of death was 72.
231
Pathophysiology Pancreatic Cancer
65% in the head, 15% body and 10% tail of pancreas. Progression from normal epithelium to invasive carcinoma follows a linear progression. Early genetic alterations include telomere shortening and mutations in the KRAS2 oncogene followed by inactivation of the p16 tumour suppressor gene.
232
Clinical manifestations Pancreatic Cancer
Key Presentations Jaundice, Non specific upper abdominal pain, weight loss and anorexia and back pain. Signs Hepatomegaly Symptoms Nausea, vomiting, early satiety, Polyuria, thirst, Steatorrhoea,
233
Investigations Pancreatic Cancer
1st Line Pancreatic CT - mass in pancreas Abdo USS - pancreatic mass, dilated bile ducts or liver metastases LFT - bilirubin, ALP and Gamma GT raised in obstructive jaundice. Gold Standard Biopsy - EUS. Others PT - prolonged FBC - low platelets and anaemia in GI bleeds Cancer antigen - elevated
234
Management Pancreatic Cancer
Stage I or II = Surgical resection with pancreatic enzyme replacement, followed by adjuvant chemotherapy Stage III or IV = Endoscopic stent insertion or palliative surgery with chemotherapy and pain management and pancreatic enzyme replacement
235
Complications Pancreatic Cancer
Surgical complications of pancreatic leaks or fistula, and early delayed gastric emptying Cholangitis DVT and pulmonary embolism
236
Prognosis Pancreatic Cancer
Average 5 year survival is 10.8% with a mean survival of 4.6 months. Stage I and II 10% of patients- 5 year survival is 20% with average of 15-18 months 50-55% patients present with metastatic disease with a survival of 3-6 months.
237
DDx Pancreatic Cancer
Chronic pancreatitis - histological features not present Bile duct stones - ERCP will rule out stricture (seen in pancreatic cancer) and confirm presence of bile duct stones Cholangiocarcinoma - CT/MRI show absence of pancreatic mass and thickening of bile duct
238
Definition Hernias
Protrusion of a viscous out of a containing cavity.
239
Epidemiology Hernias
Inguinal - more common in men Femoral - more common in women More than 20 million hernias repaired every year around the world
240
Aetiology Hernias
A combination of pressure and an opening or weakness of muscle or fascia
241
Risk Factors Hernias
Main: Male Older Chronic coughing - smokers Obesity Others: Pregnancy Family history
242
Pathophysiology Hernias
Contents of the abdominal cavity have herniated through the abdominal wall. Umbilicus, Inguinal canal, femoral region and at previous sites of surgery (incisional). Hiatus hernia, stomach passes up into chest cavity through diaphragm. Bowel that passes into a hernia can become stuck and ischaemic, called a strangulated hernia and is an emergency. Inguinal - Indirect - through deep inguinal ring and direct come into inguinal canal through defect in posterior wall of the canal. Femoral – irreducible and strangulated. Go down femoral canal and are usually found below and lateral to inguinal ligament. Umbilical - Omentum or bowel can herniate through them Epigastric - pass through linea alba above umbilicus Inscisional - appear along lines of previous incision during surgery
243
Clinical manifestations Hernias
Key Presentations pain, swelling or fullness at the site of occurrence that can change with position or Valsalva. Most common asymptomatic and appear as a bulge when cough or strain.
244
Investigations Hernias
1st Line Physical exam or Abdo CT, MRI or USS to confirm presence.
245
Management Hernias
Reducing the hernia if possible Repair - mesh technique and surgery. Patients are advised to lose weight and stop smoking before op. Patients can return to work after 2 weeks or 4 weeks for geriatric.
246
Complications Hernias
Constipation Strangulation Intestinal obstruction
247
Prognosis Hernias
1% chance that any given hernia can become strangulated.
248
DDX Hernias
Diastasis recti, Abscess, Muscle strain Soft tissue malignancy
249
Definition Paracetamol Overdose
Excessive ingestion of paracetamol leading to toxic effects.
250
Epidemiology Paracetamol Overdose
In UK, paracetamol is the most common drug taken in overdose, with 48% of poisoning hospital admissions.
251
Classifications of Paracetamol Overdose
>150mg/kg can cause serious effects and >12g is potentially fatal. Acute - <75mg / kg is unlikely to cause toxicity unless staggered. If a patient has ingested more or is in need of an urgent psychiatric assessment hospital admission is warranted. Staggered - excessive ingestion over period longer than an hour. >150mg/kg in any 24 hour period.
252
Risk factors Paracetamol Overdose
History of self harm History of frequent or repeated use of medications for pain relief Iatrogenic paracetamol poisoning following IV administration
253
Pathophysiology Paracetamol Overdose
Paracetamol is primarily metabolised in the liver. This occurs via conjugation with the addition of glucuronide to form a water soluble metabolite that can be excreted in the urine. When there is excess paracetamol, such as with overdose, conjugation become saturated and paracetamol is converted into the metabolite N-acetyl-p-benzoquinoneimine (NAPQI). NAPQI has a short half-life and is usually conjugated by the addition of glutathione, which is then renally excreted. When glutathione stores are depleted, excess NAPQI binds to hepatocellular proteins and results in oxidative damage, mitochondrial dysfunction and ultimately hepatocellular injury.
254
Clinical manifestations Paracetamol Overdose
Key Presentations Asymptomatic and mild GI symptoms. History and abdo pain. Signs scars - previous evidence of self harm, bruising, jaundice, tachycardia or coma Symptoms nausea and vomiting, anorexia, malaise, altered mental status
255
Risk assessment Paracetamol Overdose
Date, Time, Period since ingestion and Amount Weight Pregnancy Current suicidal risk
256
Investigations Paracetamol Overdose
1st Line LFT - raised ALT INR and prothrombin - raised and prolonged BG - <3.3mmol/L Creatinine - acutely elevated FBC - leukocytosis, anaemia or thrombocytopenia Gold Standard Serum paracetamol conc >700mg/L Others Urinalysis - haematuria or proteinuria Urine drug screen - positive
257
Management Paracetamol Overdose
N-acetylcysteine for 21 hour regimen. Done over 3 infusions between 1 and 16 hours. After bloods are retaken to see any hepatic impairment. However, be aware of anaphylactoid reactions which occur in 30% of patients. Acute ingestion and <8 hours - Activated charcoal, look for abnormal bloods and treatment not normally required if asymptomatic. 4 hours post ingestion do paracetamol levels and blood and assess nomogram for if NAC is required. Treatment can be stopped when INR <1.31 and ALT within normal or raised range but not more than 2x limit.
258
Complications Paracetamol Overdose
DILI ALF - acute liver failure
259
Prognosis Paracetamol Overdose
If treated it has a 0.1% mortality
260
DDx Paracetamol Overdose
DILI or alternative toxicity Hepatitis Wilson disease